News

BioNTech Plans to Build Modular mRNA Manufacturing Facilities in Africa

February 21, 2022

The turnkey facilities will promote scalable vaccine production for an end-to-end manufacturing network for mRNA-based vaccines in Africa.

Health Canada Authorizes Novavax COVID-19 Vaccine

February 18, 2022

Health Canada authorizes Novavax COVID-19 vaccine for individuals 18 years of age and older.

PETA Science Group Shares Goals With New FDA Commissioner

February 18, 2022

PETA Science Consortium International e.V. and PETA scientist Jeffrey Brown share goals with new FDA Commissioner Dr. Robert Califf.

FDA Approves Treatment for Anemia in Adults with Rare Inherited Disorder

February 18, 2022

FDA has approved Pyrukynd (mitapivat) tablets to treat hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Moderna Plans Expansion in Europe

February 18, 2022

The company has announced plans to establish a commercial presence in six European countries.

EC Approves New Drug to Treat Hemolytic Anemia in Patients with Sickle Cell Disease

February 18, 2022

EC has approved Oxbryta (voxelotor) as a treatment for hemolytic anemia in patients with Sickle Cell Disease (SCD) age 12 years and older.

EC Approves AstraZeneca’s Lupus Drug

February 18, 2022

The EC approved AstraZeneca’s Saphenlo (anifrolumab) for the treatment of active autoantibody-positive systemic lupus erythematosus.

FDA to Hold Public Symposium on Multi-Identification Biomarkers

February 17, 2022

FDA will hold a symposium discussing the identification of concepts and terminology for multi-component biomarkers from March 23–24, 2022.

Thermo Fisher Scientific Invests $40 Million to Expand Bioprocessing Manufacturing Site

February 17, 2022

Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.

Biogen and Xbrane Ink Agreement for Proposed Biosimilar

February 17, 2022

The commercialization and licensing deal will see Biogen commercialize Xbrane’s Xcimzane, a proposed biosimilar for CIMZIA (certolizumab pegol).